Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Number of Patients Affected by Candidiasis Infection
4.2.2 Growing Awareness for Candidiasis Infection
4.3 Market Restraints
4.3.1 Narrow Pipeline Molecules
4.3.2 Competition from Herbal Medicines and Alternate Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Route of Administration
5.1.1 Injection
5.1.2 Ointment
5.1.3 Oral
5.2 By Drug Type
5.2.1 Polyene
5.2.2 Azole
5.2.3 Echinocandin
5.2.4 Others
5.3 By Anatomy Type
5.3.1 Oral Candidiasis
5.3.2 Vulvovaginal Candidiasis
5.3.3 Cutaneous Candidiasis
5.3.4 Invasive Candidiasis
5.3.5 Systemic Candidiasis
5.4 By End-user
5.4.1 Hospitals and Clinics
5.4.2 Retail Pharmacies
5.4.3 Others
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Basilea Pharmaceutica Ltd.
6.1.2 Astellas Pharma Inc.
6.1.3 SCYNEXIS, Inc.
6.1.4 Pacgen Life Science Corporation
6.1.5 NovaDigm Therapeutics
6.1.6 Mycovia Pharmaceuticals, Inc.
6.1.7 Amplyx Pharmaceuticals Inc.
6.1.8 Biomar Microbial Technologies
6.1.9 Cidara Therapeutics Inc.
6.1.10 Novabiotics Limited


7 MARKET OPPORTUNITIES AND FUTURE TRENDS